U.S. Markets closed

NeoGenomics, Inc. (NEO)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Add to watchlist
9.15-0.04 (-0.44%)
At close: 4:00PM EDT

9.15 0.00 (0.00%)
After hours: 6:12PM EDT

People also watch

NeoGenomics, Inc.

12701 Commonwealth Drive
Suite 9
Fort Myers, FL 33913
United States

IndustryMedical Laboratories & Research
Full Time Employees938

Key Executives

Mr. Douglas M. VanOortChairman and Chief Exec. OfficerN/AN/A62
Mr. George A. CardozaChief Financial Officer and Sr. VPN/AN/A55
Mr. Steven C. JonesExec. VP and DirectorN/AN/A54
Dr. Maher Albitar M.D.Chief Medical Officer, Sr. VP and Director of R&DN/AN/A62
Mr. Robert J. ShovlinPres of Clinical Services DivisionN/AN/A46
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


NeoGenomics, Inc., together with its subsidiaries, operates a network of cancer-focused genetic testing laboratories providing genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, and other laboratories in the United States. It offers cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; immunohistochemistry and digital imaging testing services to localize proteins in cells of a tissue section, as well as to allow clients to see and utilize scanned slides, and perform quantitative analysis for various stains; and molecular testing services that focus on the analysis of DNA and RNA, and the structure and function of genes at the molecular level. The company also provides pathology consultation services for clients in which its pathologists review surgical samples on a consultative basis; and testing services in support of its pharmaceutical clients’ oncology programs, as well as acts as a reference laboratory supplying anatomic pathology testing services. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida.

Corporate Governance

NeoGenomics, Inc.’s ISS Governance QualityScore as of July 1, 2017 is 4. The pillar scores are Audit: 2; Board: 8; Shareholder Rights: 3; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.